Medra AI is a technology company.
Medra AI has raised $11.0M across 1 funding round.
Medra AI has raised $11.0M in total across 1 funding round.
Medra AI is a San Francisco-based startup developing a Continuous Science Platform that integrates Physical AI (autonomous robotics) and Scientific AI (reasoning models) to automate wet lab experiments, addressing data scarcity in life sciences.[1][2][3] The platform serves life science researchers and biopharma companies like Genentech, enabling high-throughput, precise data collection at scales unattainable manually, which accelerates drug discovery and scientific breakthroughs by creating self-improving feedback loops between experiments and AI models.[2][4][5] With 23 employees and recent $52 million Series A funding, Medra demonstrates strong growth momentum through partnerships and plans to build one of the largest autonomous labs in the US.[2][4][5]
Medra was founded by Michelle Lee, Ph.D., CEO, who identified critical bottlenecks in scientific data generation—such as the decades required to collect training data for models like AlphaFold2—while aiming to enable AI-driven eradication of diseases.[1][4] The idea emerged from advances in AI for robotics, computer vision, and natural language processing, leading to robotic systems that automate repetitive wet lab tasks with machine learning for perception and control.[2][6] Early traction includes collaborations with biopharma leaders like Genentech and testimonials from CSOs at Addition Tx, Pheast, and Cultivarium, culminating in the September 2025 launch of its Continuous Science Platform and a $52 million Series A in December 2025 backed by investors like PharmStars.[1][3][4][5]
Medra rides the AI-for-science wave, particularly in drug discovery, where foundation models outpace experimental validation due to data bottlenecks—pharma runs millions of experiments, but most data remains siloed and unusable for AI.[1][4] Timing aligns with robotics-AI convergence and multimodal models, amplified by market forces like biopharma's push for faster therapies amid rising costs and AI hype post-AlphaFold.[1][5] By bridging prediction-to-execution gaps with general-purpose "Physical AI Scientists," Medra influences the ecosystem, enabling ML teams to test ideas at scale, fostering reusable datasets, and scaling autonomous labs as validated by experts like Patrick Hsu of Arc Institute.[4][6]
Medra's $52 million will fuel team expansion in engineering, AI, robotics, and go-to-market, deepening biopharma partnerships and deploying larger autonomous labs.[4][5] Trends like agentic AI, closed-loop optimization, and "lab-in-the-loop" integration with ML pipelines will propel growth, potentially redefining drug development by linking predictions to outcomes for higher-success therapies.[1][4] As influence evolves, Medra could standardize AI-robotics in wet labs, powering the scientific frontier from data scarcity to abundance and solidifying its role in AI-accelerated discovery.[1][3]
Medra AI has raised $11.0M in total across 1 funding round.
Medra AI's investors include Axiom Partners, C2 Investment, Y Combinator, Akshay Kothari, Amjad Masad, Arash Ferdowsi, Balaji Srinivasan, David Petersen, Eoghan McCabe, Gokul Rajaram.
Medra AI has raised $11.0M across 1 funding round. Most recently, it raised $11.0M Seed in September 2025.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Sep 1, 2025 | $11.0M Seed | Axiom Partners, C2 Investment, Y Combinator, Akshay Kothari, Amjad Masad, Arash Ferdowsi, Balaji Srinivasan, David Petersen, Eoghan McCabe, Gokul Rajaram |